Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

modified interleukin-2 DF6215

A modified and recombinant form of the human endogenous cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon administration, modified IL-2 DF6215 targets and binds to IL-2 receptor (IL-2R) expressed on CD8+ T effector cells and activates IL-2R-mediated signaling. This enhances cytotoxic T lymphocytes (CTLs)-mediated cytotoxic immune responses against tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	modified IL-2 DF6215
Code name:	DF 6215 DF-6215 DF6215

modified interleukin-2 DF6215

Search NCI's Drug Dictionary